MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$171,841
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Accounts payable
Prepaid expenses and other curre...
Others
Negative Cash Flow Breakdown
Net loss
Payment of financing costs relat...
Operating lease liability
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-06-30
Share-based compensation
60,395
Non-cash financing costs
3,044
Amortization of operating lease right-of-use asset
58,777
Net loss
-10,427,632
Prepaid expenses and other current assets
-805,527
Operating lease liability
-62,027
Other assets
-7,766
Accrued expenses and other current liabilities
66,118
Deferred income
0
Accounts payable
1,540,535
Depreciation
7,669
Incentive tax receivable
-164,685
Financing costs related to chef purchase agreement
520,200
Acquired in-process research and development
114,399
Net cash used in operating activities
-7,140,544
Purchases of in-process research and development
12,000
Net cash used in investing activities
-12,000
Proceeds from issuance of common stock, net of issuance costs
7,803,453
Payment of financing costs related to chef purchase agreement
465,200
Proceeds from exercise and modification of warrants, net of issuance costs
-13,868
Payment of deferred offering costs
0
Net cash provided by financing activities
7,324,385
Net increase in cash
171,841
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, net of...
$7,803,453
Net cash provided by
financing activities
$7,324,385
Canceled cashflow
$479,068
Net increase in cash
$171,841
Canceled cashflow
$7,152,544
Payment of financing
costs related to chef...
$465,200
Proceeds from exercise
and modification of...
-$13,868
Accounts payable
$1,540,535
Prepaid expenses and
other current assets
-$805,527
Financing costs related to
chef purchase...
$520,200
Incentive tax receivable
-$164,685
Acquired in-process
research and development
$114,399
Accrued expenses and
other current...
$66,118
Share-based compensation
$60,395
Amortization of operating
lease right-of-use...
$58,777
Other assets
-$7,766
Depreciation
$7,669
Non-cash financing costs
$3,044
Net cash used in
operating activities
-$7,140,544
Net cash used in
investing activities
-$12,000
Canceled cashflow
$3,349,115
Net loss
-$10,427,632
Purchases of in-process
research and development
$12,000
Operating lease liability
-$62,027
Buy us a coffee
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Sonnet BioTherapeutics Holdings, Inc. (SONN)